Gastroenterology
Volume 138, Issue 3 , Pages 949-957.e7 , March 2010

Salivary Transcriptomic Biomarkers for Detection of Resectable Pancreatic Cancer

  • Lei Zhang

      Affiliations

    • School of Dentistry and Dental Research Institute, University of California-Los Angeles, Los Angeles, California
    • ,
  • James J. Farrell

      Affiliations

    • Division of Digestive Diseases, Department of Medicine, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California
    • ,
  • Hui Zhou

      Affiliations

    • School of Dentistry and Dental Research Institute, University of California-Los Angeles, Los Angeles, California
    • ,
  • David Elashoff

      Affiliations

    • Department of Biostatistics, School of Public Health, University of California-Los Angeles, Los Angeles, California
    • ,
  • David Akin

      Affiliations

    • School of Dentistry and Dental Research Institute, University of California-Los Angeles, Los Angeles, California
    • ,
  • No–Hee Park

      Affiliations

    • School of Dentistry and Dental Research Institute, University of California-Los Angeles, Los Angeles, California
    • Division of Hematology & Oncology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California
    • Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California
    • ,
  • David Chia

      Affiliations

    • Department of Pathology and Laboratory Medicine, Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California
    • ,
  • David T. Wong

      Affiliations

    • School of Dentistry and Dental Research Institute, University of California-Los Angeles, Los Angeles, California
    • Jonsson Comprehensive Cancer Center, University of California-Los Angeles, Los Angeles, California
    • Division of Head and Neck Surgery/Otolaryngology, David Geffen School of Medicine, University of California-Los Angeles, Los Angeles, California
    • Henry Samueli School of Engineering and Applied Science, University of California-Los Angeles, Los Angeles, California
    • Corresponding Author InformationReprint requests Address requests for reprints to: David T. Wong, DMD, DMSc, Felix and Mildred Yip endowed professor, Division of Oral Biology and Medicine; associate dean for research, School of Dentistry; director, Dental Research Institute, University of California at Los Angeles, 10833 Le Conte Ave, 73-017 CHS, Los Angeles, California 90095. fax: (310) 825-7609

Received 10 August 2009 ,Accepted 9 November 2009.

References 

  1. Canto MI, Goggins M, Hruban RH, et al. Screening for early pancreatic neoplasia in high-risk individuals: a prospective controlled study. Clin Gastroenterol Hepatol. 2006;4:766–781quiz 665
  2. Canto MI, Goggins M, Yeo CJ, et al. Screening for pancreatic neoplasia in high-risk individuals: an EUS-based approach. Clin Gastroenterol Hepatol. 2004;2:606–621
  3. Rulyak SJ, Kimmey MB, Veenstra DL, et al. Cost-effectiveness of pancreatic cancer screening in familial pancreatic cancer kindreds. Gastrointest Endosc. 2003;57:23–29
  4. Hoimes CJ, Moyer MT, Saif MW. Biomarkers for early detection and screening in pancreatic cancer (Highlights from the 45th ASCO annual meeting. Orlando, FL, USA. May 29-June 2, 2009). JOP. 2009;10:352–356
  5. Farrell JJ, van Rijnsoever M, Elsaleh H. Early detection markers in pancreas cancer. Cancer Biomark. 2005;1:157–175
  6. Koopmann J, Rosenzweig CN, Zhang Z, et al. Serum markers in patients with resectable pancreatic adenocarcinoma: macrophage inhibitory cytokine 1 versus CA19-9. Clin Cancer Res. 2006;12:442–446
  7. Koopmann J, Zhang Z, White N, et al. Serum diagnosis of pancreatic adenocarcinoma using surface-enhanced laser desorption and ionization mass spectrometry. Clin Cancer Res. 2004;10:860–868
  8. Rogers CD, Fukushima N, Sato N, et al. Differentiating pancreatic lesions by microarray and QPCR analysis of pancreatic juice RNAs. Cancer Biol Ther. 2006;5:1383–1389
  9. Whitcomb DC. Inflammation and cancer V. Chronic pancreatitis and pancreatic cancer. Am J Physiol Gastrointest Liver Physiol. 2004;287:G315–G319
  10. Kim JE, Lee KT, Lee JK, et al. Clinical usefulness of carbohydrate antigen 19-9 as a screening test for pancreatic cancer in an asymptomatic population. J Gastroenterol Hepatol. 2004;19:182–186
  11. Goggins M, Canto M, Hruban R. Can we screen high-risk individuals to detect early pancreatic carcinoma?. J Surg Oncol. 2000;74:243–248
  12. Locker GY, Hamilton S, Harris J, et al. ASCO 2006 update of recommendations for the use of tumor markers in gastrointestinal cancer. J Clin Oncol. 2006;24:5313–5327
  13. Pleskow DK, Berger HJ, Gyves J, et al. Evaluation of a serologic marker, CA19-9, in the diagnosis of pancreatic cancer. Ann Intern Med. 1989;110:704–709
  14. Ballantyne J. Validity of messenger RNA expression analyses of human saliva. Clin Cancer Res. 2007;13:1350–1351
  15. Nussbaumer C, Gharehbaghi-Schnell E, Korschineck I. Messenger RNA profiling: a novel method for body fluid identification by real-time PCR. Forensic Sci Int. 2006;157:181–186
  16. Zubakov D, Hanekamp E, Kokshoorn M, et al. Stable RNA markers for identification of blood and saliva stains revealed from whole genome expression analysis of time-wise degraded samples. Int J Legal Med. 2008;122:135–142
  17. Hu S, Arellano M, Boontheung P, et al. Salivary proteomics for oral cancer biomarker discovery. Clin Cancer Res. 2008;14:6246–6252
  18. Hu S, Wang J, Meijer J, et al. Salivary proteomic and genomic biomarkers for primary Sjogren's syndrome. Arthritis Rheum. 2007;56:3588–3600
  19. Li Y, St. John MA, Zhou X, et al. Salivary transcriptome diagnostics for oral cancer detection. Clin Cancer Res. 2004;10:8442–8450
  20. Mager DL, Haffajee AD, Devlin PM, et al. The salivary microbiota as a diagnostic indicator of oral cancer: a descriptive, non-randomized study of cancer-free and oral squamous cell carcinoma subjects. J Transl Med. 2005;3:27
  21. Bigler LR, Streckfus CF, Copeland L, et al. The potential use of saliva to detect recurrence of disease in women with breast carcinoma. J Oral Pathol Med. 2002;31:421–431
  22. Goldenberg RL, Culhane JF. Preterm birth and periodontal disease. N Engl J Med. 2006;355:1925–1927
  23. Streckfus CF, Mayorga-Wark O, Arreola D, et al. Breast cancer related proteins are present in saliva and are modulated secondary to ductal carcinoma in situ of the breast. Cancer Invest. 2008;26:159–167
  24. Streckfus C, Bigler L, Dellinger T, et al. The presence of soluble c-erbB-2 in saliva and serum among women with breast carcinoma: a preliminary study. Clin Cancer Res. 2000;6:2363–2370
  25. Pepe MS, Feng Z, Janes H, et al. Pivotal evaluation of the accuracy of a biomarker used for classification or prediction: standards for study design. J Natl Cancer Inst. 2008;100:1432–1438
  26. Denny P, Hagen FK, Hardt M, et al. The proteomes of human parotid and submandibular/sublingual gland salivas collected as the ductal secretions. J Proteome Res. 2008;7:1994–2006
  27. Edgar R, Barrett T. NCBI GEO standards and services for microarray data. Nat Biotechnol. 2006;24:1471–1472
  28. Hu Z, Zimmermann BG, Zhou H, et al. Exon-level expression profiling: a comprehensive transcriptome analysis of oral fluids. Clin Chem. 2008;54:824–832
  29. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143:29–36
  30. Zweig MH, Campbell G. Receiver-operating characteristic (ROC) plots: a fundamental evaluation tool in clinical medicine. Clin Chem. 1993;39:561–577
  31. Cheng Li Wong WH. DNA-chip analyzer (dChip). In:  Parmigiani G,  Garrett ES,  Irizarry R, et al. editor. The analysis of gene expression data: methods and software. New York: Springer; 2003;p. 120–141
  32. Firpo MA, Gay DZ, Granger SR, et al. Improved diagnosis of pancreatic adenocarcinoma using haptoglobin and serum amyloid A in a panel screen. World J Surg. 2009;33:716–722
  33. Li Y, Zhou X, St. John MA, et al. RNA profiling of cell-free saliva using microarray technology. J Dent Res. 2004;83:199–203
  34. Park NJ, Li Y, Yu T, et al. Characterization of RNA in saliva. Clin Chem. 2006;52:988–994
  35. Park NJ, Yu T, Nabili V, et al. RNA protect saliva: an optimal room- temperature stabilization reagent for the salivary transcriptome. Clin Chem. 2006;52:2303–2304
  36. Park NJ, Zhou X, Yu T, et al. Characterization of salivary RNA by cDNA library analysis. Arch Oral Biol. 2007;52:30–35
  37. Smith JS, Tachibana I, Pohl U, et al. A transcript map of the chromosome 19q-arm glioma tumor suppressor region. Genomics. 2000;64:44–50
  38. Kim YJ, Cho YE, Kim YW, et al. Suppression of putative tumour suppressor gene GLTSCR2 expression in human glioblastomas. J Pathol. 2008;216:218–224
  39. Okahara F, Ikawa H, Kanaho Y, et al. Regulation of PTEN phosphorylation and stability by a tumor suppressor candidate protein. J Biol Chem. 2004;279:45300–45303
  40. Okahara F, Itoh K, Nakagawara A, et al. Critical role of PICT-1, a tumor suppressor candidate, in phosphatidylinositol 3,4,5-trisphosphate signals and tumorigenic transformation. Mol Biol Cell. 2006;17:4888–4895
  41. Yim JH, Kim YJ, Ko JH, et al. The putative tumor suppressor gene GLTSCR2 induces PTEN-modulated cell death. Cell Death Differ. 2007;14:1872–1879
  42. Arcuri F, Papa S, Carducci A, et al. Translationally controlled tumor protein (TCTP) in the human prostate and prostate cancer cells: expression, distribution, and calcium binding activity. Prostate. 2004;60:130–140
  43. Chung S, Kim M, Choi W, et al. Expression of translationally controlled tumor protein mRNA in human colon cancer. Cancer Lett. 2000;156:185–190
  44. Zhu WL, Cheng HX, Han N, et al. Messenger RNA expression of translationally controlled tumor protein (TCTP) in liver regeneration and cancer. Anticancer Res. 2008;28:1575–1580
  45. Li Y, Elashoff D, Oh M, et al. Serum circulating human mRNA profiling and its utility for oral cancer detection. J Clin Oncol. 2006;24:1754–1760
  46. Mulcahy HE, Lyautey J, Lederrey C, et al. A prospective study of K-ras mutations in the plasma of pancreatic cancer patients. Clin Cancer Res. 1998;4:271–275
  47. Pellegata NS, Sessa F, Renault B, et al. K-ras and p53 gene mutations in pancreatic cancer: ductal and nonductal tumors progress through different genetic lesions. Cancer Res. 1994;54:1556–1560
  48. Gao K, Zhou H, Zhang L, et al. Systemic disease-induced salivary biomarker profiles in mouse models of melanoma and non-small cell lung cancer. PLoS One. 2009;4:e5875

 All other gene names are listed in the Supplementary Material Table S4.

 Conflicts of interest The authors disclose no conflicts.

 Funding Support was provided by the National Institutes of Health (U01DE016275 and R21CA126733).

PII: S0016-5085(09)02000-9

doi: 10.1053/j.gastro.2009.11.010

Gastroenterology
Volume 138, Issue 3 , Pages 949-957.e7 , March 2010

Article Tools

* Image Usage & Resolution